Reports
Sale
Wilson’s Disease Market Share, Trends, Outlook, Forecast: By Diagnosis Method: Blood and Urine Test, Eye Exam, Biopsy, Genetic Testing; By Treatment Type: Medications, Surgery; By Mode of Administration: Injectable, Oral, Others; By End User; By Distribution Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Wilson’s Disease Market Outlook
The Wilson’s disease market size was valued at USD 1457.5 million in 2023, driven by the rising research and development activities in drug development across the major markets. The market is expected to grow at a CAGR of 3.2% during the forecast period of 2024-2032, with the values likely to rise from USD 1498.9 million in 2024 to USD 1926.6 million by 2032.
Wilson’s Disease: Introduction
Wilson’s disease is a rare genetic condition that leads to copper level build up in several body organs, particularly, brain, eyes, and liver. Major symptoms include yellowing of skin and eyes, occurrence of golden-brown or copper-colored rings around the irises of the eyes (Kayser-Fleischer rings), along with tiredness, loss of appetite, fluid buildup in legs and stomach area. It is treated via medications and surgery in case of extreme cases.
Wilson’s Disease Market Analysis
Wilson’s disease has been treated via medications that constitute chelating agents (medicines that remove copper from the body). Penicillamine (Cupramine, Depen) and trientine (Syprine) are two commonly prescribed medications that help remove excess copper from the body. Zinc is another frequent medication that blocks copper absorption in intestines.
Wilson’s disease market demand is further fueled by the rising advancements in gene therapies. In September 2023, UC Davis Health researchers infused the first ever gene therapy in an affected patient. The clinical trial for Wilson’s disease called CYPRUS2+ displayed positive results for UX701, the investigational gene therapy treatment. It is an adeno-associated virus gene therapy that restores the function of ATP7B, that improves copper metabolism and distribution in the body.
With increasing technical advances in the medical ecosystem, scientists have been looking into finding ways to effectively devise better diagnostic methods that identify the illness at an early stage. Similarly, a better understanding of human physiology, along with hefty investments made by public and private institutions, is also poised to fuel the Wilson’s disease market value in upcoming years.
Wilson’s Disease Market Segmentation
Market Breakup by Diagnosis Method
- Blood and Urine Test
- Eye Exam
- Biopsy
- Genetic Testing
Market Breakup by Treatment Type
- Medications
- Penicillamine
- Trientine Dihydrocholoride
- Trientine Tetrahydrochoride
- Surgery
Market Breakup by Mode of Administration
- Injectable
- Oral
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Wilson’s Disease Market Overview
The United States is anticipated to dominate the Wilson’s disease market share in the forecast period. The market size can be accredited to increasing mergers and acquisitions in the region to foster better inventions for patient outcomes. Several companies are growing their product portfolios to meet the high demand for patient therapeutics.
Europe is another significant market with a robust healthcare and research infrastructure that aids market growth. The presence of prominent research and academic institutions along with leading healthcare companies also fuels market value.
Wilson’s Disease Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical
- ANI Pharmaceuticals
- Bausch Health
- DR. REDDY’S LABORATORIES LTD
- Breckenridge Pharmaceutical, Inc.
- Par pharmaceutical
- Lupin
- Panacea Biotech Ltd
- Apotex
- Navinta LLC
- Amneal Pharmaceuticals LLC.
- Meda Pharmaceuticals
- Ipsen Pharma
- Noblepharma Co., Ltd.
- Wilson Therapeutics AB
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Type |
|
| Breakup by Mode of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Wilson’s Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Wilson’s Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Wilson’s Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Wilson’s Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Wilson’s Disease Epidemiology Forecast (2017-2032)
5.3.2 France Wilson’s Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Wilson’s Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Wilson’s Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Wilson’s Disease Epidemiology Forecast (2017-2032)
5.4 Japan Wilson’s Disease Epidemiology Forecast (2017-2032)
6 Wilson’s Disease Market Overview – 7MM
6.1 Wilson’s Disease Market Historical Value (2017-2023)
6.2 Wilson’s Disease Market Forecast Value (2024-2032)
7 Wilson’s Disease Market Landscape – 7MM
7.1 Wilson’s Disease: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Wilson’s Disease Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
8 Wilson’s Disease Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Wilson’s Disease Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Wilson’s Disease Market Segmentation – 7MM
11.1 Wilson’s Disease Market by Diagnosis Method
11.1.1 Market Overview
11.1.2 Blood and Urine Test
11.1.3 Eye Exam
11.1.4 Biopsy
11.1.5 Genetic Testing
11.2 Wilson’s Disease Market by Treatment Type
11.2.1 Market Overview
11.2.2 Medications
11.2.2.1 Penicillamine
11.2.2.2 Trientine Dihydrocholoride
11.2.2.3 Trientine Tetrahydrochoride
11.2.3 Surgery
11.3 Wilson’s Disease Market by Mode of Administration
11.3.1 Market Overview
11.3.2 Injectable
11.3.3 Oral
11.3.4 Others
11.4 Wilson’s Disease Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Clinics
11.4.5 Others
11.5 Wilson’s Disease Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.6 Wilson’s Disease Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Wilson’s Disease Market
12.1 Wilson’s Disease Market Historical Value (2017-2023)
12.2 Wilson’s Disease Market Forecast Value (2024-2032)
12.3 Wilson’s Disease Market by Diagnosis Method
12.4 Wilson’s Disease Market by Treatment Type
13 EU-4 and United Kingdom Wilson’s Disease Market
13.1 Wilson’s Disease Market Historical Value (2017-2023)
13.2 Wilson’s Disease Market Forecast Value (2024-2032)
13.3 Germany Wilson’s Disease Market Overview
13.3.1 Wilson’s Disease Market by Diagnosis Method
13.3.2 Wilson’s Disease Market by Treatment Type
13.4 France Wilson’s Disease Market Overview
13.4.1 Wilson’s Disease Market by Diagnosis Method
13.4.2 Wilson’s Disease Market by Treatment Type
13.5 Italy Wilson’s Disease Market Overview
13.5.1 Wilson’s Disease Market by Diagnosis Method
13.5.2 Wilson’s Disease Market by Treatment Type
13.6 Spain Wilson’s Disease Market Overview
13.6.1 Wilson’s Disease Market by Diagnosis Method
13.6.2 Wilson’s Disease Market by Treatment Type
13.7 United Kingdom Wilson’s Disease Market Overview
13.7.1 Wilson’s Disease Market by Diagnosis Method
13.7.2 Wilson’s Disease Market by Treatment Type
14 Japan Wilson’s Disease Market
14.1 Wilson’s Disease Market Historical Value (2017-2023)
14.2 Wilson’s Disease Market Forecast Value (2024-2032)
14.3 Wilson’s Disease Market by Diagnosis Method
14.4 Wilson’s Disease Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Teva Pharmaceutical
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 ANI Pharmaceuticals
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Bausch Health
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 DR. REDDY’S LABORATORIES LTD
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Breckenridge Pharmaceutical, Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Par pharmaceutical
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Lupin
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Panacea Biotech Ltd
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Apotex
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Navinta LLC
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Amneal Pharmaceuticals LLC.
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Meda Pharmaceuticals
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Ipsen Pharma
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Noblepharma Co., Ltd.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Wilson Therapeutics AB
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Wilson’s Disease Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1457.5 million in 2023, driven by increasing research and development activities in drug development across the major markets.
The market is anticipated to grow at a CAGR of 3.2% during the forecast period of 2024-2032, likely to reach a market value of USD 1926.6 million by 2032.
The market demand is driven by the rising expenditure on medical research and development to develop better treatment methods for the disease.
The major market trend involves the application of gene therapies as a treatment alternative. In September 2023, results from a clinical trial called, CYPRUS2+ displayed positive results for UX701, the investigational gene therapy treatment for Wilson’s disease.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
The diagnosis methods include blood and urine test, eye exam, biopsy, and genetic testing.
The treatment types can be categorised into medications (penicillamine trientine dihydrocholoride and trientine tetrahydrochoride) and surgery.
The modes of administration can be divided into injectable and oral, among others.
The end users can be divided into hospitals, homecare, and specialty clinics, among other others.
The distribution channels can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Key players involved in the market are Teva Pharmaceutical, ANI Pharmaceuticals, Bausch Health, DR. REDDY’S LABORATORIES LTD, Breckenridge Pharmaceutical, Inc., Par pharmaceutical, Lupin, Panacea Biotech Ltd., Apotex, Navinta LLC, Amneal Pharmaceuticals LLC., Meda Pharmaceuticals, Ipsen Pharma, Noblepharma Co., Ltd., and Wilson’s Therapeutics AB.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER